WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report—download today for expert insights, data, and a clear view of the U.S. dredging market.→ Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

101.39 -0.79 (-0.77%)
Streaming Delayed Price Updated: 9:41 AM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Recap: Mirum Pharmaceuticals Q2 Earnings ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Expert Ratings for Mirum Pharmaceuticals ↗
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings: 
Via Benzinga
News headline image
Mirum Pharma Acquires Its Licensing Partner In Cash and Stock ↗
 
Via Benzinga
News headline image
Recap: Mirum Pharmaceuticals Q1 Earnings ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
83 Biggest Movers From Yesterday ↗
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results. 
Via Benzinga
News headline image
57 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
A Preview Of Mirum Pharmaceuticals's Earnings ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Mirum... 
Via Benzinga
News headline image
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
News headline image
Earnings Scheduled For March 9, 2022 ↗
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (... 
Via Benzinga
News headline image
Earnings Preview For Mirum Pharmaceuticals ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
News headline image
Week In Review: Huadong Pharma Enters $662 Million Deal For Two Kiniksa Anti-Inflammatory Drugs ↗
Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in southeast Asia (ex-Japan). Huadong will pay $22 million and be responsible for up to... 
Via Talk Markets
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.